NCT04853329View on ClinicalTrials.gov

Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
CD20 Positive Non Hodgkin Lymphoma
Interventions
DRUG

CPO107

CD20-CD47 Bispecific Fusion Protein

Trial Locations (1)

28204

Novant Health, Charlotte

Sponsors
All Listed Sponsors
lead

Conjupro Biotherapeutics, Inc.

INDUSTRY

NCT04853329 - Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma | Biotech Hunter | Biotech Hunter